BOSTON — Alloy Therapeutics has raised $40 million in a Series E financing round, bringing its valuation to $1 billion as the company pushes to expand its role as a technology-enabled infrastructure provider for drug discovery and development.
The Boston-based company said the funding will support growth across its core discovery platforms, downstream development services, and its artificial intelligence and data capabilities. Alloy has increasingly positioned itself as a full-service biotech platform, combining AI, real-world data, and laboratory execution to help partners move therapies from concept to clinical development more efficiently.
Since its founding in 2017, Alloy has worked with more than 200 partners across biologic modalities including antibodies, bispecifics, genetic medicines, and cell therapies. Those collaborations have produced more than 100 licensed therapeutic programs, with 22 advancing into clinical development and two reaching Phase 3 trials.
“Alloy is building the infrastructure layer connecting discovery, development, and data across the global biopharma industry. We are bridging the enormous strengths of traditional BioPharma and cutting-edge TechBio to reimagine what’s possible for making new medicine,” said Errik Anderson, Founder and CEO of Alloy Therapeutics. “Technological innovation, including AI at every step of the process, is driving a rapid evolution that no single pharma company can keep up with. Alloy’s collaborative, service-oriented model allows our partners to stay at the cutting edge without having to innovate in every dimension or hire the people and infrastructure they may only need intermittently.”
The company said it plans to use the new capital to deepen its work in antibody discovery, genetic medicines, and cell therapies, while also expanding preclinical and clinical development services. It is also investing in its AI and machine learning systems designed to integrate data across the drug development lifecycle.
Alloy’s model is aimed at supporting smaller and virtual biotech companies that require access to advanced infrastructure without building it internally. By combining proprietary AI tools with laboratory capabilities and data systems, the company said it can offer a more capital-efficient path to developing new medicines.
Investors in the round included 8VC, JIC Venture Growth Investments, Echo Capital, and several family offices, alongside existing backers such as Mubadala Capital, Presight Capital, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels, and Ulysses Diversified Holdings.
“We’ve watched Errik build Alloy methodically for nearly a decade into a company that has quietly redefined what drug development can look like at scale,” said Alex Kolicich at 8VC. “While all industries are being disrupted by AI in front of our eyes, Alloy understands that real disruption in biopharma is coming from integrating AI as part of an ‘x-in-the-loop’ strategy with real-world capabilities.”
Alloy said it continues to expand its global footprint, with centers of excellence across the United States, Japan, the Middle East, and other emerging innovation markets as it builds a decentralized model for drug development.
“Strengthening Japan’s position in global life sciences requires investing in the infrastructure that enables innovation to move faster, more efficiently, and without borders,” said Hanae Suzuki, who leads life science investments at JIC Venture Growth Investments. “Alloy’s model – connecting world-class proprietary technologies and services across geographies, including its growing presence in Japan – not only enhances Japan’s integration into the global innovation ecosystem, but also supports the development of globally competitive talent, reflecting exactly the kind of global ecosystem we seek to support.”
